Skip to content

Comparative effectof Bhallataka Vishadi Agada Lepa and Arka Taila Lepa on Eczema

A COMPARATIVE CLINICAL STUDY TO ASSESS THE EFFICACY OF BHALLATAKA VISHADI AGADA LEPA AND ARKA TAILA LEPA IN THE MANAGEMENT OF VICHARCHIKA W.S.R. ECZEMA

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030549
Enrollment
120
Registered
2021-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: EFFICACY OF ARKA TAILA LEPA IN VICHARCHIKA: Group B 60 patients will be applied Arka Taila lepa daily for 45 days Intervention2: EFFICACY OF BHALLATAKA AGADA LEPA IN VICHARCHIKA: In G

Sponsors

DR L K PATTAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed as Vicharchika on the basis of Lakshanas like Kandu, Pidaka, Shyavavarna, with or without srava and Rukshata. Patients who are willing to participate for the study

Exclusion criteria

Exclusion criteria: Patients on steroid therapy. Lesions with secondary infections. Patients who are unfit for Lepana Karma. Patients suffering from systemic disorders which interferes with the course of treatment.

Design outcomes

Primary

MeasureTime frame
bhallataka vishadi lepa contains the properties of laghu, rookshaguna, ushnaveerya, tridoshahara, kushtaghna and krimighna which acts on VicharchikaTimepoint: 45 days

Secondary

MeasureTime frame
Arka is Katu, Tikta Rasa, Laghu, Sara and Snigdha Guna, Ushna Virya, Katu Vipaka. So it balances the kapha and vata dosha on the level of skin It is beneficial in the treatment of vicharchikaTimepoint: 45 days

Countries

India

Contacts

Public ContactDR M R PANDYA

SVM AYURVEDIC MEDICAL COLLEGE

lkpattar@gmail.com9740790121

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026